U.S. markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2500-0.0100 (-0.31%)
At close: 4:00PM EDT
Sign in to post a message.
  • R
    RM
    An article in Korea Times, 2 days ago:

    https://www.koreatimes.co.kr/www/tech/2021/06/693_310497.html

    From the article:

    Moderna has 24 LNP-based mRNA development programs in its portfolios, with at least 14 having entered actual clinical studies, the company said.

    "Because LNP-based mRNA vaccines are widely being used by Pfizer and Moderna, Korean companies are greatly interested in acquiring relevant patents and hoping for transfers of technology," said the official. The U.S. Food and Drug Administration (USFDA) has recently approved Onpattro ― an mRNA-based drug that has LNP as its base ― for use.

    One problem, however, is that Moderna's LNP-based mRNA vaccine technology is being challenged for an alleged patent infringement by Arbutus Biopharma.

    This legal tussle is pressuring Moderna to pay for a license to use Arbutus' patent portfolio. Citing this situation, experts say that discussions about a possible technology transfer from Moderna can only proceed if its attempts to invalidate patents it allegedly infringed on are successful.
    [ANALYSIS] Korea sees advantages, challenges with Moderna
    [ANALYSIS] Korea sees advantages, challenges with Moderna
    www.koreatimes.co.kr
    Bullish
  • R
    RM
    http://www.koreabiomed.com/news/articleView.html?idxno=11268

    "In developing the vaccine, the company plans to apply Genevant Science's LNP technology, used in developing Pfizer and Moderna's mRNA vaccine, and its patented 5’-capping mRNA platform technology."
    Bullish
  • j
    javier
    Moderna attorney in Arbutus case changed yesterday. What would that mean?
  • J
    JC
    ABUS / MRNA court hearing scheduled in 2 weeks from today (07/01/21)! It ought to be interesting until then? Up or down? Let the games begin!
  • V
    Vicki
    The composition ratios could easily be modified. If the components of the composition were proprietary, then the components are what count, IMO.

    I don’t see how the ratios make much of a difference in terms of a legal case.
    It’s whether those components were ABUS formula components in the first place.
    Were they? If yes, then ABUS should have a strong case, right??
  • k
    k
    Last time they had this conference two years ago in June, the results were printed in the medical journal and the price doubled very quickly. As we know they had to fix a few things on their HBV portfolio but this time it seems likely successful.
  • G
    GuyGuy
    We haven't had a 2+ million share day for the past 30+ days.... Hmmm.....
    Bullish
  • k
    k
    My guess this will be double in the nearby future, pivotal points of HBV portfolio. Gigantic market.
  • s
    scam
    pls sell
    Bearish
  • T
    ThreeA
    Abus joined the Russell 3000 index, hence the rise in price and volume.
  • T
    Trev
    $ABUS is participating in the JMP Securities Life Sciences Conference - Virtual Thursday, June 17, 2021 at 11:00 am ET (Fireside Chat) 🚀
    Bullish
  • k
    k
    June 28th will be a big day. Plus pps slow increase leading up to
    Bullish
  • g
    gripsquad
    Some of the issues discussed with the MRNA include patent infringement on composition ratios.
    Bullish
  • G
    GuyGuy
    Something's up.... Any recent updates on the DE court case with MRNA? Anybody?? Thanks!!
    Bullish
  • A
    Aaron
    I come back once in a while. Everytime I am here, i see different names doing the same pumping. Moderan went from 60 to 190, but this thing is still stuck under $3. Anyone who believed anything from those pumpers are losing money.
  • J
    JAYARE
    Nice movement up with close to 3x volume!
    Bullish
  • k
    k
    This all has to do with the presentation on June 28. However it is going run up much sooner
  • J
    JAYARE
    I'll take 5% up any day/everyday!
    Bullish
  • S
    Sebas
    ABUS showed great Character when every other pharma stock went to the dump today.
    Bullish
  • j
    james
    This could be our last opportunity to load up.